Brokerages Set Phreesia, Inc. (NYSE:PHR) Target Price at $29.41

Shares of Phreesia, Inc. (NYSE:PHR) have received a consensus recommendation of “Moderate Buy” from the nineteen analysts that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seventeen have given a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $29.1176.

Several brokerages have issued reports on PHR. JPMorgan Chase & Co. lowered their target price on shares of Phreesia from $29.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday, February 20th. Wells Fargo & Company assumed coverage on shares of Phreesia in a research report on Thursday, January 8th. They set an “overweight” rating and a $30.00 price target on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Phreesia in a report on Wednesday, January 28th. Truist Financial set a $24.00 target price on shares of Phreesia in a research note on Thursday, January 8th. Finally, Zacks Research lowered Phreesia from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th.

Insider Buying and Selling

In other news, CFO Balaji Gandhi sold 8,009 shares of the stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $17.01, for a total transaction of $136,233.09. Following the completion of the transaction, the chief financial officer directly owned 156,231 shares in the company, valued at approximately $2,657,489.31. This represents a 4.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, General Counsel Allison C. Hoffman sold 6,585 shares of the firm’s stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $17.01, for a total value of $112,010.85. Following the transaction, the general counsel owned 174,762 shares of the company’s stock, valued at $2,972,701.62. This trade represents a 3.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 60,766 shares of company stock valued at $1,013,817 in the last ninety days. Company insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Phreesia

Several institutional investors have recently modified their holdings of PHR. Federated Hermes Inc. purchased a new stake in shares of Phreesia during the third quarter worth $32,000. Van ECK Associates Corp grew its stake in Phreesia by 78.7% during the 4th quarter. Van ECK Associates Corp now owns 2,502 shares of the company’s stock worth $42,000 after purchasing an additional 1,102 shares in the last quarter. Asset Management One Co. Ltd. purchased a new stake in Phreesia during the 3rd quarter worth about $45,000. KBC Group NV increased its holdings in Phreesia by 83.4% during the 4th quarter. KBC Group NV now owns 3,449 shares of the company’s stock worth $58,000 after purchasing an additional 1,568 shares during the period. Finally, Garner Asset Management Corp acquired a new stake in Phreesia in the 4th quarter valued at about $81,000. Institutional investors and hedge funds own 92.10% of the company’s stock.

Phreesia Trading Down 0.3%

PHR stock opened at $11.67 on Friday. Phreesia has a 12-month low of $11.43 and a 12-month high of $32.76. The business’s 50-day moving average is $14.94 and its 200 day moving average is $20.63. The company has a current ratio of 2.44, a quick ratio of 2.44 and a debt-to-equity ratio of 0.01. The stock has a market cap of $703.28 million, a price-to-earnings ratio of -116.64 and a beta of 0.65.

Phreesia (NYSE:PHR) last released its earnings results on Monday, December 8th. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $0.11. Phreesia had a negative return on equity of 1.31% and a negative net margin of 1.16%.The business had revenue of $120.33 million for the quarter, compared to the consensus estimate of $119.98 million. During the same quarter last year, the business posted ($0.25) earnings per share. The business’s quarterly revenue was up 12.7% compared to the same quarter last year. On average, sell-side analysts anticipate that Phreesia will post -1.1 EPS for the current fiscal year.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.